BMS-986299 manufacturers
- BMS986299
-
- $39.00
-
2026-08-16
- CAS:2242952-69-6
- Purity: 99.93%
- Supply Ability: 10g
|
| | BMS-986299 Basic information |
| Product Name: | BMS-986299 | | Synonyms: | BMS-986299;Acetamide, N-[[4-amino-7-(1H-pyrazol-3-yl)-3H-imidazo[4,5-c]quinolin-2-yl]methyl]-N-ethyl-;N-((4-Amino-7-(1H-pyrazol-5-yl)-3H-imidazo[4,5-c]quinolin-2-yl)methyl)-N-ethylacetamide;BMS986299, 10 mM in DMSO | | CAS: | 2242952-69-6 | | MF: | C18H19N7O | | MW: | 349.39 | | EINECS: | | | Product Categories: | | | Mol File: | 2242952-69-6.mol |  |
| | BMS-986299 Chemical Properties |
| Boiling point | 757.5±60.0 °C(Predicted) | | density | 1.407±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: Slightly soluble: 0.1-1 mg/ml
Ethanol: Slightly soluble: 0.1-1 mg/mlPBS (pH 7.2): Slightly soluble: 0.1-1 mg/ml | | form | Solid | | pka | 11.46±0.40(Predicted) | | color | White to off-white |
| | BMS-986299 Usage And Synthesis |
| Uses | BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A1). | | IC 50 | NLRP3: 1.28 μM (EC50) | | References | [1] Gary Glick, et al. Substituted imidazo - quinolines as nlrp3 modulators. WO2018152396A1.
[2] Gao G, et al., Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro. Front Pharmacol. 2022 Jul 5;13:906548. DOI:10.3389/fphar.2022.906548
[3] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras. |
| | BMS-986299 Preparation Products And Raw materials |
|